Results

RDF/XMLNTriplesTurtleShow queryShare ▶
SubjectPredicateObject
http://purl.uniprot.org/citations/26652611http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/26652611http://www.w3.org/2000/01/rdf-schema#comment"

Background

Methotrexate (MTX) is the most used drug for the treatment of rheumatoid arthritis (RA) although outcome differs among patients.

Aim

To evaluate whether polymorphisms in pharmacokinetic genes are associated with outcome in RA patients receiving MTX.

Patients & methods

We analyzed 28 SNPs in SLC19A1/RFC1, ABCB1, FPGS and GGH genes.

Results

We studied 194 RA patients receiving MTX monotherapy. Two FPGS SNPs, rs10987742 and rs10106, were associated with response (p = 0.033 and p = 0.041, respectively). The FPGS rs10106 variant was also associated with MTX survival (p = 0.005) and toxicity (p = 0.021). Three ABCB1 SNPs, rs868755, rs10280623 and rs1858923, were associated with toxicity (p = 0.025, p = 0.048 and p = 0.031, respectively).

Conclusion

FPGS and ABCB1 genetic variants can influence the outcome in RA patients receiving MTX monotherapy."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.org/dc/terms/identifier"doi:10.2217/pgs.15.150"xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/author"Baiget M."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/author"Salazar J."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/author"Arranz M.J."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/author"del Rio E."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/author"Casademont J."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/author"Moya P."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/author"Corominas H."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/author"Diaz-Torne C."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/date"2016"xsd:gYear
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/name"Pharmacogenomics"xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/pages"25-29"xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/title"Methotrexate pharmacokinetic genetic variants are associated with outcome in rheumatoid arthritis patients."xsd:string
http://purl.uniprot.org/citations/26652611http://purl.uniprot.org/core/volume"17"xsd:string
http://purl.uniprot.org/citations/26652611http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/26652611
http://purl.uniprot.org/citations/26652611http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/26652611
http://purl.uniprot.org/uniprot/#_F4ZUY5-mappedCitation-26652611http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26652611
http://purl.uniprot.org/uniprot/#_A1L471-mappedCitation-26652611http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26652611
http://purl.uniprot.org/uniprot/#_A4D1D2-mappedCitation-26652611http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26652611
http://purl.uniprot.org/uniprot/#_B2RDF7-mappedCitation-26652611http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26652611
http://purl.uniprot.org/uniprot/#_A8E2S6-mappedCitation-26652611http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26652611
http://purl.uniprot.org/uniprot/#_B5U2G4-mappedCitation-26652611http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26652611
http://purl.uniprot.org/uniprot/#_F4ZUQ5-mappedCitation-26652611http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/26652611
▶